Skip to main content
Premium Trial:

Request an Annual Quote

Horizon Discovery Inks Alliance with Agios Pharmaceuticals

NEW YORK (GenomeWeb News) – Horizon Discovery said today that it has signed two agreements with cancer startup Agios Pharmaceuticals related to its X-Man cell-line technology.
 
The Cambridge, UK-based firm said that it has licensed certain X-Man cell lines, including major cancer-causing genes and their matched normal genetic backgrounds. In addition, it said that it would screen a number of Agios lead compounds on a wide panel of genotypes.
 
Horizon said that its technology should enable Agios to understand how key oncogenic pathways of cancer cells survive in tumors and to predict the genomic makeup of tumors in the responsive patient types.
 
Cambridge, Mass.-based Agios will pay Horizon undisclosed up-front and renewal fees during the term of the agreements. They expect to begin the collaboration this month.

The Scan

Dropped Charges

The US Justice Department has dropped visa fraud charges against five Chinese researchers, according to the Wall Street Journal.

More Kids

The Associated Press says Moderna is expanding its SARS-CoV-2 vaccine study to included additional children and may include even younger children.

PNAS Papers on Rat Clues to Human Migration, Thyroid Cancer, PolyG-DS

In PNAS this week: ancient rat genome analysis gives hints to human migrations, WDR77 gene mutations in thyroid cancer, and more.

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.